The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies ...

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...

Autolus reported a net loss of $220.7 million for the year ended December 31, 2024, compared to $208.4 million for the same ...

GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ...

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, cutting preclinical programs and evaluating strategic options. | Despite a ...

Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said that oncology and rare ...